Detalles de la búsqueda
1.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother
; 72(1): 91-99, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35729418
2.
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
Cancer Immunol Immunother
; 71(7): 1719-1731, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34821950
3.
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Eur Respir J
; 52(4)2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262574
4.
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.
Eur Respir J
; 45(5): 1403-14, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25657019
5.
Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival.
Res Pract Thromb Haemost
; 8(2): 102359, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38666062
6.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
J Cancer Res Clin Oncol
; 149(16): 15095-15102, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37626173
7.
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.
Target Oncol
; 18(4): 585-591, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37310660
8.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Target Oncol
; 18(6): 905-914, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37966566
9.
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
J Immunother
; 2023 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37807621
10.
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Eur J Cancer
; 183: 38-48, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36801605
11.
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Eur J Cancer
; 166: 51-59, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35278825
12.
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Medicine (Baltimore)
; 99(3): e18726, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32011450
13.
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Lung Cancer
; 150: 21-25, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33045465
14.
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
J Thorac Oncol
; 15(4): 628-636, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31945494
15.
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Ther Adv Med Oncol
; 12: 1758835920937972, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32684990
16.
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.
Adv Ther
; 36(8): 2161-2166, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31154630
17.
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Lung Cancer
; 127: 96-102, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30642559
18.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Arthritis Rheumatol
; 71(12): 2100-2111, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31379105
19.
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study).
Oncotarget
; 9(9): 8253-8262, 2018 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29492192
20.
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).
Target Oncol
; 12(6): 833-838, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28762087